Home

Monday, December 2, 2019

Biocon and Mylan launch Trastuzumab Biosimilar Ogivri in US

Ogivri is approved for all indications of Herceptin, including for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).

from India Infoline News Service https://ift.tt/2qW1lj3

No comments:

Post a Comment